Summit Therapeutics SMMT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's operating cash flow?
- Summit Therapeutics (SMMT) reported operating cash flow of -$122.29M in Q1 2026.
- How has Summit Therapeutics's operating cash flow changed year-over-year?
- Summit Therapeutics's operating cash flow decreased by 99.9% year-over-year, from -$61.17M to -$122.29M.
- What is the long-term trend for Summit Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Summit Therapeutics's operating cash flow has grown at a 64.5% compound annual growth rate (CAGR), from -$72.59M to -$322.93M.
- What does operating cash flow mean?
- The net amount of cash the company generated from its day-to-day business operations.
- How do you interpret operating cash flow?
- Higher values indicate strong operational cash generation, while negative values indicate a reliance on external financing to fund operations.
- How does operating cash flow compare across companies?
- Critical benchmark for all companies; negative values are common for pre-revenue or early-stage biopharmaceutical firms.